Search research articles
Contact Us
Filters
Showing results (211-220 of 235) with videos related to
Page
of 24
Sort By:
The New England Journal of Medicine
|
October 9, 2014
Response and acquired resistance to everolimus in anaplastic thyroid cancer
Nikhil Wagle, Brian C Grabiner, Eliezer M Van Allen, et al.
Nature Medicine
|
January 31, 2020
Author Correction: A human ciliopathy reveals essential functions for NEK10 in airway mucociliary clearance
Raghu R Chivukula, Daniel T Montoro, Hui Min Leung, et al.
Cell Stem Cell
|
May 18, 2016
Mule Regulates the Intestinal Stem Cell Niche via the Wnt Pathway and Targets EphB3 for Proteasomal and Lysosomal Degradation
Carmen Dominguez-Brauer, Zhenyue Hao, Andrew J Elia, et al.
Science Advances
|
July 25, 2020
Increased lysosomal biomass is responsible for the resistance of triple-negative breast cancers to CDK4/6 inhibition
Anne Fassl, Christopher Brain, Monther Abu-Remaileh, et al.
Cancer Discovery
|
March 15, 2014
Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib
Nikhil Wagle, Brian C Grabiner, Eliezer M Van Allen, et al.
Biorxiv : the Preprint Server for Biology
|
April 22, 2024
Ergothioneine boosts mitochondrial respiration and exercise performance via direct activation of MPST
Hans-Georg Sprenger, Melanie J Mittenbühler, Yizhi Sun, et al.
Cancer Research
|
February 26, 2013
Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR
Qingsong Liu, Chunxiao Xu, Sivapriya Kirubakaran, et al.
Biorxiv : the Preprint Server for Biology
|
October 3, 2025
Atlas of Lysosomal Aging Reveals a Molecular Clock of Storage Disorder-Associated Metabolites
Anna M Puszynska, Thao P Nguyen, Andrew L Cangelosi, et al.
Nature
|
June 4, 2013
The bromodomain protein Brd4 insulates chromatin from DNA damage signalling
Scott R Floyd, Michael E Pacold, Qiuying Huang, et al.
Aging Cell
|
June 18, 2016
Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an α-glucosidase inhibitor or a Nrf2-inducer
Randy Strong, Richard A Miller, Adam Antebi, et al.
Page
of 24
Search research articles
Search
Showing results (211-220 of 235) with videos related to
Sort By:
Page
of 24
The New England Journal of Medicine
|
October 9, 2014
Response and acquired resistance to everolimus in anaplastic thyroid cancer
Nikhil Wagle, Brian C Grabiner, Eliezer M Van Allen, et al.
Nature Medicine
|
January 31, 2020
Author Correction: A human ciliopathy reveals essential functions for NEK10 in airway mucociliary clearance
Raghu R Chivukula, Daniel T Montoro, Hui Min Leung, et al.
Cell Stem Cell
|
May 18, 2016
Mule Regulates the Intestinal Stem Cell Niche via the Wnt Pathway and Targets EphB3 for Proteasomal and Lysosomal Degradation
Carmen Dominguez-Brauer, Zhenyue Hao, Andrew J Elia, et al.
Science Advances
|
July 25, 2020
Increased lysosomal biomass is responsible for the resistance of triple-negative breast cancers to CDK4/6 inhibition
Anne Fassl, Christopher Brain, Monther Abu-Remaileh, et al.
Cancer Discovery
|
March 15, 2014
Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib
Nikhil Wagle, Brian C Grabiner, Eliezer M Van Allen, et al.
Biorxiv : the Preprint Server for Biology
|
April 22, 2024
Ergothioneine boosts mitochondrial respiration and exercise performance via direct activation of MPST
Hans-Georg Sprenger, Melanie J Mittenbühler, Yizhi Sun, et al.
Cancer Research
|
February 26, 2013
Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR
Qingsong Liu, Chunxiao Xu, Sivapriya Kirubakaran, et al.
Biorxiv : the Preprint Server for Biology
|
October 3, 2025
Atlas of Lysosomal Aging Reveals a Molecular Clock of Storage Disorder-Associated Metabolites
Anna M Puszynska, Thao P Nguyen, Andrew L Cangelosi, et al.
Nature
|
June 4, 2013
The bromodomain protein Brd4 insulates chromatin from DNA damage signalling
Scott R Floyd, Michael E Pacold, Qiuying Huang, et al.
Aging Cell
|
June 18, 2016
Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an α-glucosidase inhibitor or a Nrf2-inducer
Randy Strong, Richard A Miller, Adam Antebi, et al.
Page
of 24